What CTX value indicates a moderate risk of BRONJ?

What CTX value indicates a moderate risk of BRONJ?

• A. Below 100
• B. 100-150
• C. 150-200
• D. Above 200

Answer: (B)

The CTX (C-terminal telopeptide of type I collagen) value that indicates a moderate risk of bisphosphonate-related osteonecrosis of the jaws (BRONJ) falls within the range of 100-150. This value is crucial because it helps in assessing the risk of developing BRONJ in patients who are undergoing bisphosphonate therapy. When the CTX level is between 100 and 150, it suggests that the bone turnover is sufficiently low, which can predispose the patient to the development of complications in the jaw, especially after surgical procedures. A CTX value below 100 indicates a higher risk, while values above 150 generally suggest a lower risk of developing BRONJ as bone turnover increases. Thus, understanding the significance of CTX levels is critical for managing and counseling patients who are on bisphosphonate therapy. Monitoring these levels helps healthcare providers make informed decisions about surgical interventions and patient management to minimize the risk of BRONJ.

The CTX (C-terminal telopeptide of type I collagen) value that indicates a moderate risk of bisphosphonate-related osteonecrosis of the jaws (BRONJ) falls within the range of 100-150. This value is crucial because it helps in assessing the risk of developing BRONJ in patients who are undergoing bisphosphonate therapy. When the CTX level is between 100 and 150, it suggests that the bone turnover is sufficiently low, which can predispose the patient to the development of complications in the jaw, especially after surgical procedures.

A CTX value below 100 indicates a higher risk, while values above 150 generally suggest a lower risk of developing BRONJ as bone turnover increases. Thus, understanding the significance of CTX levels is critical for managing and counseling patients who are on bisphosphonate therapy. Monitoring these levels helps healthcare providers make informed decisions about surgical interventions and patient management to minimize the risk of BRONJ.